Canada markets closed

Taro Pharmaceutical Industries Ltd. (TARO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
42.20-0.03 (-0.07%)
At close: 04:00PM EDT
42.20 +0.01 (+0.02%)
After hours: 04:02PM EDT

Taro Pharmaceutical Industries Ltd.

14 Hakitor Street
Haifa Bay
Haifa 2624761
Israel
972 4 847 5700
https://www.taro.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees1,554

Key Executives

NameTitlePayExercisedYear Born
Mr. Uday V. BaldotaCEO & DirectorN/AN/A1970
Mr. William J. CooteVP, CFO & Chief Accounting OfficerN/AN/A1955
Mr. Itamar KarsentiVP & Head of OperationsN/AN/A1972
Mr. Avi AvramoffVP and Head of R&DN/AN/A1965
Mr. Itzik BaruchVice President of Technical ServicesN/AN/A1963
Dr. Roman KaplanVice President of Scientific and Technical Compliance ManagerN/AN/A1947
Mr. Erik Zwicker J.D.VP, General Counsel & SecretaryN/AN/A1980
Mr. Ara AprahamianVice President of Sales & Marketing616.14kN/A1968
Ms. Michele VisoskyVP & Head of Human ResourceN/AN/A1966
Mr. Jayesh ShahHead of ProcurementN/AN/A1956
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic. The company provides its products in the form of capsule, cream, drops, emulsion, gel/gel kit, granules, injectable, lotion, oil, ointment, paste, powder/powder for solution, rectal suppository, shampoo, solution/solution for infusion, spray, suspension, syrup, tablets, toothpaste and mouthwash, topical foam, and topical solution. It distributes and sells its products directly to wholesalers, retail drug chains, food chains, hospitals, mass merchandisers, e-commerce stores, and other direct consumers, as well as healthcare institutions and private pharmacies. The company was incorporated in 1959 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Alkaloida Chemical Company Zrt. As of June 30, 2023, Taro Pharmaceutical Industries Ltd. operates as a subsidiary of Sun Pharmaceutical Industries Limited.

Corporate Governance

Taro Pharmaceutical Industries Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.